المؤلفون: Rayson VC; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Harris MA; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Savas P; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Hun ML; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Virassamy B; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Salgado R; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium., Loi S; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.

المصدر: Trends in cancer [Trends Cancer] 2024 Jun; Vol. 10 (6), pp. 490-506. Date of Electronic Publication: 2024 Mar 22.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101665956 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-8025 (Electronic) Linking ISSN: 24058025 NLM ISO Abbreviation: Trends Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/immunology , Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/therapy , Triple Negative Breast Neoplasms*/pathology , Biomarkers, Tumor*/immunology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/pharmacology , Tumor Microenvironment*/immunology , Tumor Microenvironment*/drug effects , Neoadjuvant Therapy*/methods, Humans ; Female ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Prognosis ; Chemotherapy, Adjuvant/methods